Info, Abstracts, and Alpha

[BTH]

Dalotuzumab failure

One more reason why Merck needs an MTOR to combine with their IGFR1:

CHICAGO—The addition of dalotuzumab (MK-0646) to cetuximab and irinotecan (Ir) failed to improve progression-free survival (PFS) and overall survival (OS) in patients with chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC), according to study investigators at the American Society of Clinical Oncology's 2011 Annual Meeting. Predictive biomarker analysis is ongoing to identify subpopulations that may have benefit from dalotuzumab therapy during the trial.

David J. Watkins, MBBS, of The Royal Marsden Hospital, London, UK, and colleagues sought to determine if dalotuzumab improved PFS and OS in combination with cetuximab and irinotecan in patients with KRAS wild-type mCRC in this randomized, placebo-controlled, multicenter, international, Phase 2/3 study. Eligible patients had previously failed both irinotecan and oxaliplatin and had progressed on or within 3 months of their last therapy.